title: Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
abstract: Histone deacetylase inhibitors are a group of recently developed compounds that modulate cell growth and survival. We evaluated the effects of the histone deacetylase inhibitor MGCD0103 on growth of pancreatic carcinoma models following single agent treatment and in combination with gemcitabine. MGCD0103 inhibited tumor cell growth and acted synergistically with gemcitabine to enhance its cytotoxic effects. Gene expression analysis identified the cell cycle pathway as one of the most highly modulated gene groups. Our data suggest that MGCD0103 + gemcitabine might be an effective treatment for gemcitabine-refractory pancreatic cancer.
authors.affiliation: Celgene, San Francisco, California, USA. vsung@celgene.com
authors.forename: Victoria
authors.initials: V
authors.lastname: Sung
authors.forename: Normand
authors.initials: N
authors.lastname: Richard
authors.forename: Helen
authors.initials: H
authors.lastname: Brady
authors.forename: Armin
authors.initials: A
authors.lastname: Maier
authors.forename: Gerhard
authors.initials: G
authors.lastname: Kelter
authors.forename: Carla
authors.initials: C
authors.lastname: Heise
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004357:Drug Synergism; D015870:Gene Expression; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D015151:Immunoblotting; D010179:Pancreas / Q000201:enzymology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D011743:Pyrimidines / Q000494:pharmacology*; D000093542:Gemcitabine
chemical_list: D001549:Benzamides; D056572:Histone Deacetylase Inhibitors; D011743:Pyrimidines; D003841:Deoxycytidine; C523184:mocetinostat; D000093542:Gemcitabine